Wedbush Cuts Beam Therapeutics' Price Target to $100 From $152, Citing Liver Programs Timeline, Lowered Ramp for BEAM-101; Outperform Rating Kept
Wedbush Cuts Beam Therapeutics' Price Target to $100 From $152, Citing Liver Programs Timeline, Lowered Ramp for BEAM-101; Outperform Rating Kept
韋德布什將BEAM Treateutics的目標價從152美元下調至100美元,理由是肝臟計劃時間表,下調了BEAM-101的斜率;保持跑贏評級
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊